Aksigen Hospital Care
Aksigen Hospital Care is a privately held Indian pharmaceutical company founded in 1994 that develops and markets anti-inflammatory systemic enzyme therapies (Trypsin, Bromelain & Rutoside combinations) and muscle cramp relief products for Orthopaedic, Plastic surgery, and General surgery specialists across PAN India.
- Company typePrivate
- Founded1994
- HeadquartersMumbai, India
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aksigen Hospital Care does
Aksigen Hospital Care (AHC) is a privately held, research-driven pharmaceutical company headquartered in Mumbai, India, founded in 1994 with a mission to introduce pathbreaking therapies in the anti-inflammatory space. The company pioneered systemic enzyme therapy in India and was the first Indian firm to launch the combination of Trypsin, Bromelain & Rutoside (TBR) for anti-inflammatory use, also developing the first and only dispersible formulation of TBR in the world. AHC received DCGI approval for the TBR combination after conducting a clinical trial in 300+ patients to establish safety and efficacy, and later extended the franchise into bone and joint disorder management. Its product portfolio centers on Elastros Pack (a combination of Minerals, Vitamins and amino acids for skeletal muscle cramp relief) and TBR-based therapies, serving Orthopaedic, Plastic surgery, and General surgery therapeutic areas.
The company operates a WHO GMP compliant manufacturing facility at MIDC, Ambarnath, dedicated to tablets and capsule formulations, and runs a PAN India sales and distribution operation that covers more than 100,000 retail outlets through a professional field sales team and direct engagement with healthcare institutions. AHC generates revenue primarily through domestic pharmaceutical product sales (one-time license-style transactions through retail distribution), supplemented by regional contract manufacturing services and technology transfer/licensing arrangements that it is actively pursuing for select overseas markets. Customer engagement is concentrated on orthopaedic practitioners, plastic surgeons, and general surgeons, with end-use patients (particularly those with skeletal muscle cramps) constituting the downstream consumer base.
The company is privately held with no disclosed parent company, no public funding rounds, and no institutional investor involvement visible in the source material. Strategic posture is consistent with a niche specialty pharmaceutical operator: focused portfolio, regulatory first-mover status in TBR, proprietary novel formulation technology, broad retail distribution, and selective openness to in-licensing and overseas contract manufacturing as alternative growth vectors.
Aksigen Hospital Care firmographics
Firmographics- Name
- Aksigen Hospital Care
- Legal name
- AKSIGEN Hospital Care
- Website
- https://aksigen.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Aksigen Hospital Care is a privately held Indian pharmaceutical company founded in 1994 that develops and markets anti-inflammatory systemic enzyme therapies (Trypsin, Bromelain & Rutoside combinations) and muscle cramp relief products for Orthopaedic, Plastic surgery, and General surgery specialists across PAN India.
- Ownership category
- akta.pro rank
Aksigen Hospital Care industry classification
Industry- Product category
- Anti-inflammatory Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
Keywords
Where Aksigen Hospital Care is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices2 records
Markets served
Aksigen Hospital Care business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Product Sales (Domestic): Revenue generated from sale of proprietary pharmaceutical products including Elastros (muscle cramp relief) and TBR-based therapies through domestic distribution network covering 100,000+ retail outlets across India.
- Contract Manufacturing: Regional contract manufacturing services for select countries as an alternative business model to expand overseas presence.
- Technology Transfer: Technology transfer arrangements for expediting availability of products in select countries through partnerships and licensing arrangements.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
Aksigen Hospital Care product offering
Product offeringCore offering
Aksigen Hospital Care manufactures and markets proprietary pharmaceutical formulations, primarily anti-inflammatory systemic enzyme therapies based on the Trypsin, Bromelain & Rutoside (TBR) combination and the Elastros Pack (minerals, vitamins and amino acids) for skeletal muscle cramp relief. Products are produced at a WHO GMP compliant facility in MIDC, Ambarnath and sold domestically through a professional sales team reaching 100,000+ retail outlets, targeting prescribers in orthopaedics, plastic surgery and general surgery.
Product overview
Aksigen Hospital Care is a pharmaceutical company offering a focused portfolio of drug therapies primarily in the anti-inflammatory and musculoskeletal space. The core product is Elastros Pack, a combination of Minerals, Vitamins, and amino acids for treating skeletal muscle cramps. Additionally, the company pioneered systemic enzyme therapy in India with its TBR (Trypsin, Bromelain & Rutoside) combination, including a novel dispersible formulation. The portfolio serves therapeutic areas including Orthopaedics, Plastic surgery, and General surgery.
Differentiator
Problem solved
Functional benefit
Products and services
- Elastros Pack
Quantifiable outcome
- Established safety and efficacy through clinical trial in 300+ patients for DCGI approval
Companies that use Aksigen Hospital Care
Customer profileSegments4 records
Ideal customer profiles2 records
Aksigen Hospital Care technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Aksigen Hospital Care partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- In-licensing Partners (unnamed)coreAHC seeks opportunities to in-license new products and technologies that fit with their development strategy and therapeutic areas of focus (Orthopaedics, Plastic surgery, General surgery). The company supports development of long-term alliances to create synergistic value through collaboration and flexibility.
- Regional Contract Manufacturing Partners (unnamed)minorAHC is open to exploring alternative business models including regional contract manufacturing for expediting availability of its products in select countries. Also open to technology transfers.
Scale indicators4 records
Recent moves5 records
Expansion highlights4 records
Aksigen Hospital Care competitors and assessment
Company assessmentBroad incumbents
- Ajanta Pharma: Mid-to-large Indian specialty pharmaceutical company with branded formulations in multiple therapeutic specialties including pain management; overlapping therapeutic and distribution profile.
- Alkem Laboratories: Large Indian pharmaceutical company with broad branded specialty portfolio overlapping AHC's anti-inflammatory and surgical care therapeutic areas; competes in the same India hospital-channel segment.
- Torrent Pharmaceuticals: Large Indian pharmaceutical company with branded specialty franchise in pain, inflammation, and orthopaedic segments; comparable therapeutic overlap with AHC's core products.
- Mankind Pharma: One of India's largest domestic pharmaceutical companies with deep pan-India retail distribution; competes with AHC in the same retail channels and many of AHC's therapeutic categories.
- Cipla: India's largest pharmaceutical companies by revenue, with a broad branded specialty portfolio that includes anti-inflammatory and surgical-care products overlapping AHC's therapeutic areas.
Direct peers
- Unichem Laboratories: Indian specialty pharmaceutical manufacturer with branded formulations in musculoskeletal, anti-inflammatory, and pain segments; similar mid-sized niche pharma profile to AHC.
- TTK Healthcare: Indian healthcare and pharmaceutical group with a focused branded pharma portfolio, including orthopaedic and surgical-adjacent therapeutic areas; comparable niche-branded positioning to AHC.
- Modi Mundipharma: India-based specialty pharma with branded pain and anti-inflammatory portfolio serving orthopaedic and surgical specialties, directly comparable to AHC's therapeutic focus and India-centric distribution model.
- Troikaa Pharmaceuticals: Indian specialty pharmaceutical company focused on branded formulations in pain management and post-surgical care; comparable to AHC's niche branded approach in anti-inflammatory and surgical therapeutics.
Regional players
- Zuventus Healthcare (Emami Group): India-focused mid-sized branded pharma with presence in orthopaedic and pain management segments; comparable niche-branded positioning in the same Indian market as AHC.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Aksigen Hospital Care social profiles
Digital presenceAksigen Hospital Care compliance and trust
Trust signalCompliance1 record
Aksigen Hospital Care financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aksigen Hospital Care leadership team
Management profileNumber of profiles
Aksigen Hospital Care funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aksigen Hospital Care M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aksigen Hospital Care
What does Aksigen Hospital Care do?
Aksigen Hospital Care manufactures and markets proprietary pharmaceutical formulations, primarily anti-inflammatory systemic enzyme therapies based on the Trypsin, Bromelain & Rutoside (TBR) combination and the Elastros Pack (minerals, vitamins and amino acids) for skeletal muscle cramp relief. Products are produced at a WHO GMP compliant facility in MIDC, Ambarnath and sold domestically through a professional sales team reaching 100,000+ retail outlets, targeting prescribers in orthopaedics, plastic surgery and general surgery.
Is Aksigen Hospital Care a public or private company?
Aksigen Hospital Care is a private company. It is classified as unknown and is currently operating.
When was Aksigen Hospital Care founded?
Aksigen Hospital Care was founded in 1994. It employs 251 to 500 people.
Where is Aksigen Hospital Care based?
Aksigen Hospital Care is headquartered in Mumbai, India, in the Asia region.
How does Aksigen Hospital Care make money?
Three revenue lines are on record. Pharmaceutical Product Sales (Domestic) is the primary driver. The others are contract Manufacturing and technology Transfer.
Who are Aksigen Hospital Care's main competitors?
Broad incumbents on record are Ajanta Pharma, Alkem Laboratories, Torrent Pharmaceuticals, Mankind Pharma and Cipla. Direct peers are Unichem Laboratories, TTK Healthcare, Modi Mundipharma and Troikaa Pharmaceuticals. Zuventus Healthcare (Emami Group) is listed as a regional player.
Does Aksigen Hospital Care have an API?
No public API is recorded for Aksigen Hospital Care.
What industry is Aksigen Hospital Care in?
Aksigen Hospital Care's product category is Anti-inflammatory Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.